Elravie Re2O

**Elravie Re2O** is an injectable, particulated human acellular dermal matrix skin-booster product developed by L&C Bio. It consists of decellularized allogeneic human dermis that retains extracellular-matrix architecture and structural components, while cellular material associated with immune rejection is removed using the company's Alloclean processing technology. The product is intended for intradermal aesthetic skin restoration, including improvement of skin texture, density, elasticity, pores, fine lines, and photoaging-associated roughness. Its proposed activity is physical extracellular-matrix supplementation and remodeling rather than pharmacologic binding to a defined molecular receptor. L&C Bio lists Re2O as an injectable acellular allograft dermis product, and a randomized split-face clinical study evaluated Elravie Re2O with hyaluronic acid versus hyaluronic acid alone for facial skin roughness. ([lncbio.co.kr](https://www.lncbio.co.kr/bbs/board.php?bo_table=products1_en&locale=en_US&wr_id=14))

Brand names

Elravie Re2O

Other names

Re2ORe-2ORe 2O